Abstract Objectives: This study aims at reporting 2 cases of primary ovarian carcinoid tumor, and providing an adequate registry of such cases and how they were managed. Methods: 2 female patients with primary ovarian carcinoid were diagnosed and treated in our center. Discussion of their presentation, pathology and treatment is entitled. Also a thorough search of all published registries and case reports of ovarian carcinoid was done with analysis of reported data. Results: 164 cases of primary ovarian carcinoid tumor were detected since 2005 with the
Background
Ovarian carcinoid tumors may be primary or metastatic (mostly from GIT origin). Differentiation is usually difficult, but bilaterality, peritoneal deposits, absence of teratomatous element, and lymphovascular invasion are signs of metastatic carcinoid [1] ; more recent studies suggested that immunohistochemistry with CDX2 may be of value in differentiating carcinoids of GIT origin [2] . Primary carcinoid tumor of the ovary represents less than 1% of all carcinoid tumors and less than 0.1% of all ovarian neoplasms. Two thirds of these tumors manifest as a localized lesion, while about one third presents with distant spread [3] . Most tumors are seen in perimenopausal women, commonly presenting with ovarian heterogeneous mass, or as an incidental finding in abdominal radiology done for other purpose. Histologically, according to WHO, there are four major variants of primary ovarian carcinoid: insular, trabecular, strumal, mucinous and mixed (insular and trabecular) [4] . 30% of patients with carcinoids have symptoms of the carcinoid syndrome, mainly affecting patients with insular type, while it rarely occurs with trabecular type. Extremely rare cases presented with an intractable constipation mainly due to peptide YY which inhibits intestinal motility [5, 6] . Primary ovarian carcinoid may occur on top of teratoma or in an otherwise normal ovary. Surgery remains the cornerstone for treatment of localized cases with excellent prognosis.
Methods
This study reports 2 different cases of primary ovarian carcinoid who attended the Oncology Center Mansoura University (OCMU) in 2014, and aims to review and register all published cases since 2005 till March 2016.
Case report one
Malignant ovarian carcinoid on top of teratoma.
Female patient 59 years old, postmenopausal with 5 offspring, hypertensive and hepatic (HCV + ve) with no surgical history, presented with abdominal pain, enlargement and bloating to her gynecologist, who recommended computerized tomography. CT revealed right ovarian mass 9 Â 11 Â 7.3 cm mostly cystic with irregular outline with omental metastasis and moderate ascites.
The patient was referred to our center (OCMU) where revision of CT suggested ovarian cancer, and after multidisciplinary panel discussion the decision was exploration.
Exploration was done on March 2014 under general anesthesia with a midline incision where about one liter of ascites was aspirated and sent for cytology, followed by right salpingo-oophrectomy and frozen section. The frozen pathology revealed malignant ovarian neoplasm, so complete staging laparotomy in the form of total abdominal hysterectomy, contralateral salpingo-oophrectomy, omentectomy, bilateral iliac lymphadenectomy and random peritoneal biopsies was done.
Postoperative pathology showed a malignant carcinoid tumor of the right ovary mostly on top of teratoma (insular variant) with no lymphovascular emboli with Ki67 <2% (Fig. 1) . Left ovary, omentum and peritoneal biopsies were free with reactive hyperplasia of 14 dissected lymph nodes.
Patient was sent home at 4th day postoperative with drain output of 300c.c serous discharge.
The patient was readmitted one week later to the ICU with wound infection, low grade fever and disturbed conscious level. Investigations showed mildly elevated liver enzymes (SGOT = 65), mild deterioration of renal function (Cr = 2.3), leucocytosis (20,000) mainly neutrophilia, thrombocytosis (620), hyperbilirubinemia (1.5), respiratory alkalosis (PH = 7.42, CO 2 = 35 and HCO 3 = 21), hypernatremia (160), hypocalcemia (Ca = 6.5) and normal potassium (K = 5). The condition was recognized as severe sepsis leading to hepatic pre-coma and unusual electrolyte disturbances. The patient was managed by wound drainage, liver supports, IV fluids and electrolyte replacement.
The patient was re-discharged 5 days latter with good general status.
No chemotherapy was given and patient was scheduled for follow up every 6 months in 1st two years. No evidence of recurrence was detected in radiology after two years of follow up.
Case report two
Pure ovarian carcinoid tumor.
Female patient was aged 48 years with liver cirrhosis and surgical history of splenectomy followed by hernioplasty for incisional hernia one year later. CT (pre-excision) was done revealing large, well defined, bilobed solid and cystic mass in the right adenexal region with multiple areas of calcifications contacting and compressing right psoas muscle 6 Â 11 cm suggestive of dermoid cyst. Left simple ovarian cyst 3 cm was also detected.
Unilateral right salpingo-oophrectomy was done outside our center. Postoperative pathology revealed a carcinoid tumor (trabecular variant) with positive chromogranin and synaptophysin, and Ki67 <2% (Fig. 2) . CT after the operation was free. Serum 5-HIAA = 8.9.
Multidisciplinary panel at OCMU decision was completion hysterectomy, omentectomy and appendectomy which was done at November 2014 with postoperative pathology free of tumor tissue. Patient remains disease free after one and half year of follow up.
Registry
Although population based registries of primary ovarian carcinoid tumors are deficient, multiple researchers had made efforts on registering and analyzing reported cases of these tumors. The last of this published registry up to our knowledge was Modlin et al. [3] at 2003. A thorough search on pubmed, medline and google was done with headings (primary ovarian carcinoid, carcinoid on top of teratoma and malignant transformation of teratoma) and all reported cases since 2005 till March 2016 were registered (Table 1) .
From the collected data we recognized 52 cases with insular variant (commonest pathology), 21 cases with trabecular variant, 20 cases with strumal variant, mixed variant in 4 cases and mucinous in 1 case with the remaining 66 case non-specified (Fig. 3) . The mean age was 50 years. The average tumor size was about 11 cm. Most of the cases were pure carcinoid (68 cases) while carcinoid transformation of a benign teratoma occurs in 45 cases (51 cases were unreported) (Fig. 4) .
Functioning ovarian carcinoid causing endocrine symptoms occurs rarely (only 25 cases). 14 cases manifested with carcinoid heart disease (2 of which were diagnosed in postmortem pathology). Another 9 cases manifested with constipation, which was related to polypeptide secretion. Only one case presented with Cushing syndrome and one with hyperinsulinemia (Fig. 5 ). More interestingly all cases documented with constipation were strumal variant and none of the cases with trabecular variant were functioning.
Associated tumors occur in only 16 cases (mucinous cystadenoma = 5, contra-lateral ovarian epithelial cancer = 1, liver metastasis = 2, strumal thyroid cancer + breast cancer = 1, endometrial cancer + gliomatosis peritonii = 1, teratoma of contra-lateral ovary = 1, nodal recurrence = 1, gall bladder carcinoid = 1, ovarian ependymoma + MEN1 = 1, pseudomyxoma peritonii = 1, colonic lymphangiocele = 1). Primary ovarian carcinoid Treatment was extremely variable, most cases underwent total abdominal hysterectomy and bilateral salpingooophrectomy (13 cases); three of them completed surgery after initial oophrectomy and paraffin section. Other surgeons preferred complete staging laparotomy with lymphadenectomy as for epithelial ovarian cancer (8 cases). Bilateral salpingooophrectomy was done in 6 cases; while fertility sparing surgery (unilateral salpingo-oophrectomy) was done in 10 cases with no documentation of long term follow up except one case with 2 year disease free survival. In the remaining 127 cases treatment was not reported.
From the collected data there were 164 cases of primary ovarian carcinoid reported since the beginning of 2005 till March 2016 adding to this our 2 case reports, making a total of 658 cases of primary ovarian carcinoid reported since first diagnosed at 1939 till now.
Is there a rule for appendectomy in treatment of primary ovarian carcinoid
Although it is a commonly performed practice aiming to exclude appendiceal origin, there is no consensus on it and all cases were negative in our review and in our case report. In spite of this some experts prefer doing appendectomy in the mucinous variant of carcinoid.
Discussion
Neuroendocrine tumors are relatively rare tumors arising from APUD cells of neuroectodermal origin (previously called APUDomas); they include Medullary thyroid cancer, Merkel cell carcinoma, pheochromocytoma, pancreatic islet cell tumors, carcinoid tumors (bronchopulmonary, GIT and thymus) and neuroendocrine tumors of the gynecological tract. Neuroendocrine tumors are usually sporadic, but may arise in the context of syndromes as MEN, Von Hippel Lindau and neurofibromatosis [62] . Neuroendocrine tumors of the ovary include: poorly differentiated high grade variants (small cell & large cell NETs) and well differentiated indolent variants known as carcinoids [63] .
Ovarian carcinoid tumors were first described in 1939 by Stewart et al. [64] . Since then, multiple case reports were published. At 2000 Soja et al. published an important analysis of ovarian carcinoid tumors registered worldwide [65] . In his paper 329 cases of primary ovarian carcinoid were analyzed with 57% occurring on top of teratoma and 47% occurring as pure form. He concluded that pure forms were larger in size (average 8.9 cm), had higher rates of metastases (22%) and a higher incidence of carcinoid syndrome (22.9%) [57] . The second large registry of primary ovarian carcinoid was Modlin et al. [3] at 2003 in which 492 cases were described. Approximately 66% of them were localized lesions, while about 31% present with distant spread. Unfortunately, in his paper Modlin did not differentiate cases occurring as pure form from those occurring on top of teratoma.
Mature teratoma of the ovary is known to be the most common ovarian tumor, representing 20% of all ovarian neoplasms. Malignant transformation of teratoma was described, although rare. The commonest overlying malignancy was squamous cell carcinoma [66] , followed by adenocarcinoma then carcinoid tumor.
Carcinoid tumors secrete a great variety of neurohumoral substances including; serotonin, histamine, tachykinin, bradykinin, kallikrein, corticotrophin, substance P, motilin, and prostaglandins [67] . Persistent body exposure to large quantities of these hormones and amines result in carcinoid syndrome with the classic triad of; flushing of arms and face, wheezes, and diarrhea. Normally, carcinoid syndrome does not occur with an intestinal carcinoid until it has metastasized or in the presence of hepatic dysfunction or hepatic shunts (as TIPS), because of the efficient hepatic detoxification of secreted substances. However, functioning primary ovarian 
ConsƟpaƟon
Cushing Hyperinsulinemia Figure 5 Hormonal presentation of ovarian carcinoid tumors.
carcinoid tumors can cause these symptoms directly, because their venous drainage bypasses the portal venous system [68] . Trabecular carcinoid variant was never associated with carcinoid syndrome. Carcinoid syndrome was absent in both cases in our report. The insular type is the commonest variant of primary ovarian carcinoid, followed by the strumal and trabecular types; while mucinous carcinoids are the least common. Bearing in mind that metastatic carcinoids in the ovary are mostly of insular type, the diagnostic problem is in these cases, and are only occasionally with trabecular or mucinous types [21] .
Immunohistochemistry is crucial in the diagnosis of primary carcinoid tumors of the ovary. Synaptophysin and chromogranin are the classic markers. CD56 may be used, but is nonspecific. Estrogen and progesterone receptors are always negative, in contrast to adenocarcinoma. TTF1 and CDX2 may be used to differentiate primary from secondary carcinoid tumors [10] . Most primary ovarian carcinoids are stage I on FIGO system with tumor confined to one ovary, while few cases with advanced disease were reported [7] .
Clinical and pathological prognostic factors of the neoplasm are the basic determinants of the therapeutic strategy in these rare cases, because of the absence of evidence-based guidelines. Cyst wall invasion, intra-operative rupture of the ovarian tumor and disseminated tumor are considered unfavorable prognostic factors [69] .
Premenopausal women with tumors confined to the ovary may be treated with fertility-sparing surgery, as tumors are usually unilateral and carry a good prognosis, but careful staging to exclude occult metastases is important. However, in the absence of controlled trials to validate this approach, hysterectomy with bilateral salpingo-oophrectomy and surgical debulking of extra-ovarian spread and/or metastases is the treatment of choice [47] , using the commonly taught dictum ''diagnose as rare and treat as common". In rare patients with mucinous variant of ovarian carcinoid, omentectomy and para-aortic lymph node dissection may also be needed because these tumors spread mainly through lymphatics [63] .
Anesthesia of those patients with carcinoid syndrome can be challenging due to extreme hemodynamic lability and exaggerated physiologic responses to trivial stimuli. Recommendations include: titrated induction of anesthesia and avoidance of catecholamines and sympathomimetic drugs because these drugs may trigger a carcinoid crisis. In addition perioperative cover with an Octreotide infusion reduces the risks [70] [71] [72] [73] [74] .
Conclusion
Primary ovarian carcinoid is a rare tumor with only 658 cases reported worldwide up-to-date. Diagnosis should be confirmed by immunohistochemistry, and secondary carcinoid should be excluded. Extensive sampling of any solid part within a mature teratoma is emphasized not to miss a focus of carcinoid. Adequate treatment is not well defined, but surgery still the main line with chemotherapy reserved for those with high proliferative index as measured by Ki67. Somatostatin analog is only used for those with functioning tumors as confirmed by urine 5-HIAA and/or serum chromogranin.
